PMID- 26766421
OWN - NLM
STAT- MEDLINE
DCOM- 20170113
LR  - 20170113
IS  - 1651-2251 (Electronic)
IS  - 0001-6489 (Linking)
VI  - 136
IP  - 5
DP  - 2016
TI  - Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their 
      prognostic significance: a retrospective clinical study.
PG  - 506-13
LID - 10.3109/00016489.2015.1126856 [doi]
AB  - CONCLUSION: The melanoma-associated antigens A1, -A9, -A11 (MAGE-A1, -A9, -A11) 
      are relatively tumor-specific in laryngeal squamous cell carcinoma (LSCC), and 
      could be ideal antigens for LSCC immunotherapy. In addition, MAGE-A9 probably is 
      a poor prognostic marker for LSCC patients. OBJECTIVE: The MAGE-A family belongs 
      to Cancer/testis antigens (CTA). However, the expression pattern of MAGE-A1, 
      MAGE-A9, and MAGE-A11 in LSCC is still unclear. This study aims to evaluate the 
      expression and possible prognostic role of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC 
      patients. METHODS: The expression of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC 
      specimens was investigated by immunohistochemistry, and the association of their 
      expression and the clinical parameters and the survival of LSCC patients were 
      analyzed by chi-square test, Kaplan-Meier survival and Cox regression analysis. 
      RESULTS: The expression rates of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC were 
      54.7%, 46.2%, and 51.9%, respectively. The expression of MAGE-A1, MAGE-A9, and 
      MAGE-A11 in LSCC was correlated with clinical stage, lymph node metastasis, and 
      tumor size. The overall survival of LSCC patients with positive MAGE-A1, MAGE-A9, 
      or MAGE-A11 expression was lower than the patients without MAGE-A1, MAGE-A9, or 
      MAGE-A11 expression. Cox's multivariable analysis showed that MAGE-A9 expression 
      was an independently poor prognostic factor for LSCC patients.
FAU - Liu, Shenghui
AU  - Liu S
AD  - a Research Center, the Fourth Hospital of Hebei Medical University , Shijiazhuang 
      , Hebei , PR China ;
AD  - b Department of Otolaryngology , the Fourth Hospital of Hebei Medical University 
      , Shijiazhuang , Hebei , PR China.
FAU - Sang, Meixiang
AU  - Sang M
AD  - a Research Center, the Fourth Hospital of Hebei Medical University , Shijiazhuang 
      , Hebei , PR China ;
FAU - Xu, Yuru
AU  - Xu Y
AD  - b Department of Otolaryngology , the Fourth Hospital of Hebei Medical University 
      , Shijiazhuang , Hebei , PR China.
FAU - Gu, Lina
AU  - Gu L
AD  - a Research Center, the Fourth Hospital of Hebei Medical University , Shijiazhuang 
      , Hebei , PR China ;
FAU - Liu, Fei
AU  - Liu F
AD  - a Research Center, the Fourth Hospital of Hebei Medical University , Shijiazhuang 
      , Hebei , PR China ;
FAU - Shan, Baoen
AU  - Shan B
AD  - a Research Center, the Fourth Hospital of Hebei Medical University , Shijiazhuang 
      , Hebei , PR China ;
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160114
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Melanoma-Specific Antigens)
SB  - IM
MH  - Carcinoma, Squamous Cell/diagnosis/*metabolism/mortality
MH  - China/epidemiology
MH  - Humans
MH  - Laryngeal Neoplasms/diagnosis/*metabolism/mortality
MH  - Melanoma-Specific Antigens/*metabolism
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
OTO - NOTNLM
OT  - MAGE-A1
OT  - MAGE-A11
OT  - MAGE-A9
OT  - laryngeal squamous cell carcinoma (LSCC)
OT  - prognosis
EDAT- 2016/01/15 06:00
MHDA- 2017/01/14 06:00
CRDT- 2016/01/15 06:00
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2017/01/14 06:00 [medline]
AID - 10.3109/00016489.2015.1126856 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2016;136(5):506-13. doi: 10.3109/00016489.2015.1126856. Epub 
      2016 Jan 14.